Search results
US FDA approves Neurocrine Biosciences' movement disorder drug
Reuters· 19 hours ago, opens new tab Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition ...
FDA, doctors warn about compounded Ozempic. What we found at metro weight loss clinics
WFXT via Yahoo News· 1 day agoIt’s a popular drug that millions of people are taking to lose weight, but the federal government...
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer
Clinical Trials Arena via Yahoo Finance· 16 hours agoOn 18 April 2024, the US Food and Drug Administration (FDA) approved Roche’s Alecensa (alectinib),...
FDA approves Boehringer Ingelheim’s Cyltezo for inflammatory ailments
Pharmaceutical Technology via Yahoo Finance· 21 hours agoThe US Food and Drug Administration (FDA) has approved Boehringer Ingelheim's high-concentration,...
FDA has completed its testing for bird flu in milk, dairy products — and more
WGN Chicago via Yahoo News· 7 hours agoThe Danish drug maker will spend six and a half billion to increase production. Ozempic is an FDA-...
FDA Approves First Drug for WHIM Syndrome
MedPage Today· 4 days agoCXCR4 antagonist mavorixafor effectively boosts neutrophils and lymphocytes to reduce infections
Apple Watch is FDA's first-ever approved digital AFib history device
AppleInsider· 19 hours agoApple Watch has had an atrial fibrillation feature since 2022, and the FDA approved its use just...
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
NBC Philadelphia· 7 days agoThe Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder,...
Ozempic maker Novo Nordisk denies flooding market with 'junk' patents after FTC challenge
Quartz· 15 hours agoThe Ozempic maker denied wrongdoing, stating that the disputed patents — including for its popular...
FTC Weighs In on Orange Book Listing of Drug-Device Patents | JD Supra
JD Supra· 23 hours agoBackground: For many years, FDA has failed to respond substantively to requests from drug makers for clarity regarding which types of patents that cover ...